The management of patients with atrial fibrillation and dronedarone's place in therapy

Advances in Therapy

Volumn 28, Issue 12, 2011, Pages 1059-1077

  Cohen, Marc ^a   Boiangiu, Catalin ^a  

^a NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

Amiodarone; Antiarrhythmic agents; Arrhythmias; Atrial fibrillation; Cardiac; Dronedarone

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; DRONEDARONE; DRUG DERIVATIVE;

AGE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); DRUG EFFECT; HEART ATRIUM FIBRILLATION; HEART RATE; HUMAN; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; SEX DIFFERENCE;

AGE FACTORS; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; HEART RATE; HUMANS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; SEX FACTORS;

EID: 84860558213     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-011-0086-1     Document Type: Review

References (70)

1. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009;104:1534-1539.
2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370-2375.
3. Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol. 2011;57:e101-e198.
4. Tsang TS, Miyasaka Y, Barnes ME, Gersh BJ. Epidemiological profile of atrial fibrillation: a contemporary perspective. Prog Cardiovasc Dis. 2005;48:1-8.
5. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year followup of the Renfrew/Paisley study. Am J Med. 2002;113:359-364.
6. Coyne KS, Paramore C, Grandy S, Mercader M, Reynolds M, Zimetbaum P. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health. 2006;9:348-356.
7. Kim MH, Lin J, Hussein M, Battleman D. Incidence and temporal pattern of hospital readmissions for patients with atrial fibrillation. Curr Med Res Opin. 2009;25:1215-1220.
8. Patel PP, Johnston SJ, Lin J, Schulman KL, Naccarelli GV. Cost burden of hospitalization and mortality in United States atrial fibrillation/flutter patients (abstract PO03-53). Presented at: Heart Rhythm; May 13-16, 2009; Boston, MA.
9. Kim MH, Lin J, Hussein M, Kreilick C, Battleman D. Cost of atrial fibrillation in United States managed care organizations. Adv Ther. 2009;26:1-11.
10. Kim MH, Klingman D, Lin J, Pathak P, Battleman DS. Cost of hospital admission for antiarrhythmic drug initiation in atrial fibrillation. Ann Pharmacother. 2009;43:840-848.
11. Hagens VE, Ranchor AV, Van Sonderen E, et al. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol. 2004;43:241-247.
12. Dorian P, Jung W, Newman D, et al. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. J Am Coll Cardiol. 2000;36:1303-1309.
13. Paquette M, Roy D, Talajic M, et al. Role of gender and personality on quality-of-life impairment in intermittent atrial fibrillation. Am J Cardiol. 2000;86:764-768.
14. Wattigney WA, Mensah GA, Croft JB. Increased atrial fibrillation mortality: United States, 1980- 1998. Am J Epidemiol. 2002;155:819-826.
15. Atrial fibrillation as a contributing cause of death and Medicare hospitalization - United States, 1999. MMWR Morb Mortal Wkly Rep. 2003;52:128,130- 131.
16. Hohnloser SH. New pharmacological options for patients with atrial fibrillation: the ATHENA trial. Rev Esp Cardiol. 2009;62:479-481.
17. Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;123:104-123.
18. Michaud GF, John R. Percutaneous pulmonary vein isolation for atrial fibrillation ablation. Circulation. 2011;123:e596-e601.
19. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369-2429.
20. Caro JJ. An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation. Am J Manag Care. 2004;10:S451-S458.
21. Food and Drug Administration. FDA approves Pradaxa to prevent stroke in people with atrial fibrillation [press release]. Available at: www.fda. gov/NewsEvents/Newsroom/PressAnnouncements/ucm230241.htm. Accessed July 13, 2011.
22. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation. 2011;123:2562-2570.
23. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
24. Food and Drug Administration. FDA approves Xarelto to prevent stroke in people with common type of abnormal heart rhythm [press release]. Available at: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm278646.htm. Accessed November 7, 2011.
25. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.
26. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806-817.
27. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.
28. Krishnamoorthy S, Lip GY. Antiarrhythmic drugs for atrial fibrillation: focus on dronedarone. Expert Rev Cardiovasc Ther. 2009;7:473-481.
29. Vidaillet H, Greenlee RT. Rate control versus rhythm control. Curr Opin Cardiol. 2005;20:15-20.
30. Gopinathannair R, Sullivan RM, Olshansky B. Update on medical management of atrial fibrillation in the modern era. Heart Rhythm. 2009;6:S17-S22.
31. Olshansky B, Rosenfeld LE, Warner AL, et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol. 2004;43:1201-1208.
32. Segal JB, McNamara RL, Miller MR, et al. The evidence regarding the drugs used for ventricular rate control. J Fam Pract. 2000;49:47-59.
33. Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2005;46:e1-82.
34. Van Gelder I, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362:1363-1373.
35. Wegener FT, Ehrlich JR, Hohnloser SH. Dronedarone: an emerging agent with rhythmand rate-controlling effects. J Cardiovasc Electrophysiol. 2006;17(Suppl. 2):S17-S20.
36. Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005;352:1861-1872.
37. Corley SD, Epstein AE, DiMarco JP, et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation. 2004;109:1509-1513.
38. Pedersen OD, Brendorp B, Elming H, Pehrson S, Kober L, Torp-Pedersen C. Does conversion and prevention of atrial fibrillation enhance survival in patients with left ventricular dysfunction? Evidence from the Danish Investigations of Arrhythmia and Mortality ON Dofetilide/(DIAMOND) study. Card Electrophysiol Rev. 2003;7:220-224.
39. Snow V, Weiss KB, LeFevre M, et al. Management of newly detected atrial fibrillation: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Intern Med. 2003;139:1009- 1017.
40. Kim MH, Klingman D, Lin J, Battleman DS. Patterns and predictors of discontinuation of rhythm-control drug therapy in patients with newly diagnosed atrial fibrillation. Pharmacotherapy. 2009;29:1417-1426.
41. Prystowsky EN. Atrial fibrillation: dronedarone and amiodarone-the safety versus efficacy debate. Nat Rev Cardiol. 2010;7:5-6.
42. Pacerone [package insert]. Minneapolis, MN: Upsher-Smith Laboratories, Inc.; 2008.
43. Cordarone [package insert]. Philadelphia, PA: Wyeth Laboratories; 2004.
44. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med. 2000;342:913-920.
45. Kopelman HA, Horowitz LN. Efficacy and toxicity of amiodarone for the treatment of supraventricular tachyarrhythmias. Prog Cardiovasc Dis. 1989;31:355-366.
46. Goldschlager N, Epstein AE, Naccarelli GV, et al. A practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm. 2007;4:1250-1259.
47. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet. 1997;350:1417-1424.
48. Kim MH, Lin J, Hussein M, Battleman D. Incidence and economic burden of suspected adverse events and adverse event monitoring during AF therapy. Curr Med Res Opin. 2009;25:3037-3047.
49. Ishak KJ, Proskorovsky I, Guo S, Lin J. Persistence with antiarrhythmics and the impact on atrial fibrillation-related outcomes. Am J Pharm Benefits. 2009;1:193-200.
50. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-1833.
51. Laughlin JC, Kowey PR. Dronedarone: a new treatment for atrial fibrillation. J Cardiovasc Electrophysiol. 2008;19:1220-1226.
52. Multaq [package insert]. Bridgewater, NJ: Sanofi- Aventis US LLC; 2011.
53. Freemantle N, Lafuente-Lafuente C, Mitchell S, Eckert L, Reynolds M. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide and propafenone, for the management of atrial fibrillation. Europace. 2011;13:329-345.
54. Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357:987-999.
55. Davy JM, Herold M, Hoglund C, et al. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for The cOntrol of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J. 2008;156:527-529.
56. Kober L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358:2678- 2687.
57. Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360:668-678.
58. Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM. A short-term, randomized, doubleblind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010;21:597-605.
59. Tschuppert Y, Buclin T, Rothuizen LE, et al. Effect of dronedarone on renal function in healthy subjects. Br J Clin Pharmacol. 2007;64:785-791.
60. Page RL, Connolly SJ, Crijns HJ, et al. Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial). Am J Cardiol. 2011;107:1019-1022.
61. Connolly SJ, Crijns HJ, Torp-Pedersen C, et al. Analysis of stroke in ATHENA: A placebo- controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation. 2009;120:1174-1180.
62. Torp-Pedersen C, Page RL, Connolly SJ, et al. The effect of dronedarone on hospitalizations in patients with atrial fibrillation. Results from the ATHENA study [abstract 4101]. Circulation. 2008;118:S828.
63. Sanofi-Aventis. Sanofi-Aventis initiates 10,000 patient study with Multaq® in permanent AF [press release]. Available at: www.prnewswire. com/news-releases/sanofi-aventis-initiates- 10000-patient-study-with-multaqr- inpermanent- af-93551119.html. Accessed July 13, 2011.
64. Sanofi-Aventis. Sanofi provides Multaq phase IIIb PALLAS trial update. Available at: en.sanofi.com/binaries/20110707-PALLAS-en-tcm28-33021.pdf. Accessed July 13, 2011.
65. Food and Drug Administration. FDA drug safety communication: multaq (dronedarone) and increased risk of death and serious cardiovascular adverse events. Available at: www.fda.gov/Drugs/DrugSafety/ucm264059.htm. Accessed October 31, 2011.
66. Food and Drug Administration. FDA Drug Safety Communication: Severe liver injury associated with the use of dronedarone (marketed as Multaq). Available at: www.fda.gov/Drugs/DrugSafety/ucm240011.htm. Accessed July 13, 2011.
67. Food and Drug Administration. Potential signals of serious risks/new safety information identified by the adverse event reporting system (AERS) between July - September 2010. Available at: www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ ucm237585.htm. Accessed March 21, 2011.
68. QuaterWatch: 2010 Quarter 1. Monitoring MedWatch Reports. Signals for acetaminophen, dronedarone and botulinum toxin products [executive summary]. Available at: freepdfhosting. com/078147c86d.pdf. Accessed March 21, 2011
69. Naccarelli GV, Johnston SS, Lin J, Patel PP, Schulman KL. Cost burden of cardiovascular hospitalization and mortality in ATHENA-like patients with atrial fibrillation/atrial flutter in the United States. Clin Cardiol. 2010;33:270-279.
70. European Medicines Agency. European Medicines Agency recommends restricting use of multaq. Available at: www.ema.europa.eu/ema/index.jsp?curl= pages/news-and-events/news/2011/09/news-detail-001344.jsp&murl=menus/ news-and-events/news-and-events.jsp&jsenabled=true. Accessed November 3, 2011.